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Since Jules Freund reported that crude mycobacterial
extracts greatly promoted immune responses to antigens
(1), the use of adjuvants has become a widespread, but
poorly understood practice to promote T and B cell re-
sponses (2). Recent studies have begun to identify the
chemical nature of several adjuvants and the cellular and
molecular mechanisms of their long-elusive immunologi-
cal effects. For example, conserved microbial structures are
recognized by innate immunity receptors such as Toll-like
receptors (TLRs) and the complement system, eliciting
specific signaling cascades which, ultimately, result in en-
hancing and guiding T and B cell responses (for reviews,
see references 3 and 4).
Despite these considerable advances, the task of enhanc-
ing CD8 T cell priming to nonliving antigens, a major goal
of vaccines against a range of infectious and cancer diseases,
has eluded immunologists. In this issue, Gonzalez-Aseguino-
laza and colleagues report that 
 
 
 
-galactosylceramide (
 
 
 
-Gal-
Cer), a glycolipid originally extracted from marine sponges
on the basis of its antitumor properties, promotes anti-
malarial CD8 T cell immunity when coinjected with irradi-
ated sporozoites (5). Unlike common microbial adjuvants,
which signal through TLRs, 
 
 
 
-GalCer functions as an anti-
 
gen presented by CD1d to NKT cells expressing a con-
 
served semi-invariant 
 
  
 
 TCR (for a review, see refer-
ence 6). Like microbial adjuvants, however, 
 
 
 
-GalCer
activates dendritic cells (DCs), though it does so indirectly
through the cognate interaction with CD1d-restricted
 
 
 
-GalCer–specific NKT cells. DCs are the antigen-pre-
senting cell type that is central to adaptive immunity (7),
and it is likely that the efficacy of different adjuvants can be
explained by differences in signaling DCs to undergo the
complex and coordinate maturation events that are re-
quired for efficient T cell priming. Here, we will review
 
the emerging families of adjuvant-specific receptors, high-
lighting the recent recognition that specialized subsets
lymphocytes, such as NKT cells, can function at the in-
nate phase of immunity to promote and regulate adaptive
immunity through interactions with DCs.
 
Toll Receptors.
 
Purified and synthetic components of
microbial extracts exert potent adjuvant effects (for recent
reviews, see references 8–10). These include a variety of
lipids and glycolipids, such as mycolic acid, lipoarabi-
nomannan (LAM), LPS, lipoteichoic acid and microbial
GPI, polynucleotides, such as bacterial DNA (i.e., with un-
methylated CpG sequences) and double stranded RNA
(produced upon viral infection), lipoproteins, and even a
conserved protein, flagellin, which enables bacterial motil-
ity. Surprisingly, most of their effects now appear to be me-
diated by receptors belonging to a single gene family, the
TLRs. Although Toll was originally discovered for its con-
tribution to dorsoventral patterning in 
 
Drosophila
 
 embryos
through an intracellular cascade homologous to the nuclear
factor (NF)-
 
 
 
B signaling pathway, later studies identified
the critical role of Toll in the fly innate immune response
to microbial infection (11). Remarkably, there appeared to
be some specificity in both the input and output of the Toll
pathways. Thus, whereas fungi and G
 
 
 
 bacteria activated
the antifungal peptide gene 
 
drosomycin
 
 through Toll, G
 
 
 
bacteria activated the anti-G
 
 
 
 peptide 
 
diptericin
 
 through a
distinct Toll-like pathway. These observations have sug-
gested a simple and powerful scenario whereby innate im-
munity receptors not only recognize conserved microbial
structures directly, as signatures of class of pathogen, but
also trigger an effector response that is tailored to the
pathogen. The discovery of TLRs in vertebrates and their
connection to costimulatory ligand and cytokine induction
by antigen-presenting cells have been a prelude to an ex-
plosion of knowledge, which has assigned most of the effects
of microbial adjuvants to one of ten distinct TLR family
members (see Fig. 1). Moreover, triggering the TLRs by
microbial adjuvants, such as CFA, is not only sufficient for
the activation of the adaptive immune responses, but it
appears to be required for the induction of Th1 effector
responses (12). Interestingly, adjuvants that do not trigger
TLRs, such as alum, which is devoid of microbial compo-
nents, tend to potentiate Th2 responses.
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Although it is tempting to speculate that, as in 
 
Drosophila
 
,
specificity upstream and downstream of individual TLRs
will connect different classes of pathogens to different
classes of immune responses, there are important differ-
ences in the mechanisms of Toll function between humans
and flies. For example, several lines of evidence suggest that
mammalian TLRs may recognize their ligands directly, in
some cases with the help of accessory proteins (for a re-
view, see reference 8). In contrast, the 
 
Drosophila
 
 Toll is in-
duced by a self-protein Spatzle, which is processed and ac-
tivated by a proteolytic cascade triggered by infection.
Thus, the microbial recognition step in flies occurs up-
stream of Toll and was recently shown to be mediated by a
soluble peptidoglycan recognition protein (PGRP) (13).
Another unresolved issue is how signal transduction differ
between different TLRs, given the similarity of their intra-
cytoplasmic domains. The recent discovery of additional
signaling pathways connected to different TLRs is likely to
shed light on this question (14–16).
 
Complement Receptors.
 
Microbial carbohydrates activat-
ing the complement cascade elicit a distinct adjuvant path-
way which is mediated by the complement receptor CD21
expressed on B cells in association with the signaling mole-
cule CD19. Linked recognition of antigen by the BCR and
covalently attached C3d by CD21 amplifies, through Vav-
mediated activation of lipid and protein kinases, BCR sig-
naling, allowing detection of minute concentrations of an-
tigen that would otherwise fail to stimulate B cells (17, 18).
Thus, C3d-antigen fusion proteins may be of great interest
for B cell vaccine strategies.
 
Invariant TCRs.
 
NKT cells are a specialized subset of
CD1d-restricted autoreactive T cells which is reported to
regulate various conditions ranging from type I diabetes to
tumor rejection in vivo through the release of Th1 or Th2
cytokines (for a review, see reference 6). 
 
 
 
-GalCer, which
was originally extracted from marine sponges based on its
anti-tumor properties (19), binds CD1d and is recognized
at picomolar concentrations by the conserved semi-invari-
ant, CD1d-restricted 
 
  
 
 TCR of mouse (V
 
 
 
14-J
 
 
 
18/
V
 
 
 
8) and human (V
 
 
 
24-J
 
 
 
18/V
 
 
 
11) NKT cells (20). It is
thought therefore that 
 
 
 
GalCer acts as a surrogate antigen
mimicking an as yet unidentified self-antigen which is
loaded onto CD1d in the endosomal compartment. In
vivo, as little as 1 ng of 
 
 
 
-GalCer injected systemically into
mice induces activation of NKT cells, which explosively
release both Th1 and Th2 cytokines and elicit a down-
stream cascade of activation spreading to DCs (B7 and IL-
12 induction), NK cells (IFN-
 
 
 
 secretion and killer func-
tion), and B cells (B7 induction) (21–24). In this issue,
Gonzalez-Aseguinolaza and colleagues (5) report that 
 
 
 
-Gal-
Cer should be added to the arsenal of vaccine adjuvants, as
was predicted from the range of its biological effects, but
also that it exhibits the rare property of enhancing CD8 T
cell–mediated immunity against malaria infection when
coinjected with irradiated sporozoites. Priming anti-malar-
ial CD8 T cells with a nonliving antigen likely requires the
coordinate induction of several fundamental steps in the
maturation program of DCs, including the expression of
 
costimulatory molecules and IL-12, MHC class I–mediated
antigen processing and presentation through the exogenous
pathway, and homing to the T cell areas of the spleen. In
that regard, one potential advantage of 
 
 
 
-GalCer over the
TLR-mediated adjuvants may be that NKT cells engage
in rich, cognate interaction with DCs, which include
CD40L/CD40 signaling, an essential step for CD8 T cell
priming (25–27) as well as exposure to a range of cytokines
and chemokines (Fig. 1).
 
 
 
-GalCer is a promising immunomodulatory agent
which is currently being explored for its potential benefits
in antitumor and antiinfectious therapies as well as in the
prevention of type I diabetes and autoimmune encephalo-
myelitis (28–36). A unique property of the NKT/
 
 
 
-Gal-
Cer adjuvant pathway is the ability to induce both Th1
and Th2 immunity. However, it is not yet fully under-
stood how NKT cells can promote Th2 immunity in some
cases and Th1 in others, and future research is warranted
to better control and exploit this versatility of 
 
 
 
-GalCer
(21, 33, 37).
Interestingly, there are similar subsets of specialized lym-
phocytes straddling innate and adaptive immunity which
express invariant receptors for which surrogate ligands are
available (for a review, see reference 6). For example, a
large proportion of circulating 
 
  
 
 T cells in humans ex-
press V
 
 
 
9 TCR which can uniformly be activated by syn-
thetic phosphoantigens. Other invariant 
 
  
 
 TCR ex-
pressed by specialized populations in the skin and mucosal
tissues are actively studied and it is envisioned that in the
near future, they could be exploited as well for site-specific
vaccine strategies.
The discovery of surrogate synthetic antigens which
uniformly activate whole subsets of innate lymphocytes
such as CD1d-restricted NKT cells and V
 
 
 
9 
 
  
 
 T cells
not only lends support to the view that these cells belong
to the innate rather than the adaptive arm of the immune
system, more resembling NK cells than conventional T
cells, but also considerably extends the scope and promise
of adjuvant research.
 
Other Adjuvants.
 
Products released by necrotic cell
death and stressed or damaged tissues can act as powerful
adjuvants as well (38–40). Interestingly, physiological apop-
tosis does not activate, and may even in some cases sup-
press, immunity. These endogenous adjuvant effects indi-
cate that cell injury and tissue damage alone, in the absence
of foreign microbial elements, activate immunity. Thus,
they may account for the various forms of anti–self-immune
responses which do not seem to be associated with micro-
bial infection, including many chronic autoimmune dis-
eases and some acute, transient response to damaged tissues,
for example after mycocardial infarction. They may also ac-
count for transplant rejection and allergy (7, 41).
The coexistence of endogenous, sterile, and exogenous,
microbial adjuvants supports the idea that evolution se-
lected diverse mechanisms enabling the detection of both
indirect (damage) and direct (pathogen structures) signa-
tures of infection. It has been suggested that some micro-
bial adjuvants might in fact mimic endogenous signs of 
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damage (42) or, to the contrary, that endogenous adju-
vants might mimic microbial products (4). Elucidating the
nature of these endogenous adjuvants associated with
stress and damage will not only shed light on these theo-
retical issues, but also will undoubtedly bring novel in-
sights into the inner workings of the immune response to
stress and damage and its general involvement in immu-
nity and autoimmunity.
 
DCs.
 
Ultimately, it is striking that all microbial and
nonmicrobial T cell adjuvant pathways intersect at the
level of the DC, the antigen-presenting cell type which is
central to the priming of adaptive T cell responses. Adju-
vant cascades are complex, involving a number of molecu-
lar and cellular activation events, but their effects on dis-
tinct steps of the maturation program of DCs provide an
attractive framework to envision the future dissection of
adjuvanticity. For example, activation of DCs regulates in
a coordinate manner the induction of costimulation and
cytokines such as IL-12, the antigen processing and pre-
sentation pathways, including the exogenous pathway of
MHC class I presentation, and the tissue migration pattern.
A detailed molecular understanding of the impact of adju-
vant signaling on these processes will be required to eluci-
date the basis for the qualitative and quantitative differ-
ences between adjuvants.
 
Conclusion.
 
Underlying the emerging diversity of adju-
vants and the expanding universe of corresponding recep-
tors is the simple concept that, whether self or foreign,
conserved structures exposed during tissue damage and mi-
crobial invasion constitute important cues for several fami-
lies of receptors of innate immunity. These innate immu-
nity receptors in turn activate, in a variety of cell types,
specialized effector pathways designed by evolution to
meet the threat of individual pathogens. Of importance to
future strategies of T cell vaccination against intracellular
infections and tumors is the convergence of all T cell adju-
vants to one cell type, the DC, and specifically the effects
of adjuvants on the coordinate maturation program that
underlies efficient antigen presentation by DCs for priming
CD4 and CD8 T cell responses.
Undoubtedly, many more natural adjuvants remain to be
discovered. The paper by Gonzalez-Aseguinolaza in this is-
sue (5) illustrates the unusual story and the potentially im-
portant role of a glycolipidic adjuvant which was originally
extracted from marine sponges. It also draws attention to
subsets of lymphocytes expressing rearranged, but con-
served, TCR or BCR, which may function at the innate
rather than adaptive phase of immunity and could be har-
nessed to promote and guide adaptive immunity, particu-
larly against intracellular infections and tumors.
Understanding the structural details of the recognition
of adjuvants by innate immunity receptors, the intracellular
signaling and the intercellular communication network
that they trigger is a major challenge of future research. In
Figure 1. Adjuvant pathways. Various classes of microbial or nonmicrobial adjuvants are specifically recognized by invariant receptors such as TLRs
expressed by DCs, soluble complement factors, or even invariant TCRs expressed by specialized subsets of CD1d-restricted NKT    T cells and    T
cells. The resulting adjuvant cascades generally lower the antigen concentration required to trigger the adaptive B or T cell responses, and/or provide cy-
tokines which favor Th1 or Th2 differentiation. 
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particular, it is envisioned that such research will generate
the knowledge required for the rational design of a new
generation of adjuvants tailored to elicit specific effector
functions.
 
The authors thank A.M. Silverstein for discussion.
 
Submitted: 15 January 2002
Revised: 21 January 2002
Accepted: 5 February 2002
 
References
 
1. Freund, J., and K. McDermott. 1942. Sensitization to horse
serum by means of adjuvants. 
 
Proc. Soc. Exp. Biol. Med.
 
 49:
548–553.
2. Janeway, C.A. 1989. Approaching the asymptote? Evolution
and revolution in immunology. 
 
Cold Spring Harb. Symp.
Quant. Biol.
 
 54:1–13.
3. Fearon, D.T., and R.M. Locksley. 1996. The instructive role
of innate immunity in the acquired immune response. 
 
Science.
 
272:50–54.
4. Medzhitov, R., and C.A. Janeway, Jr. 1997. Innate immu-
nity: the virtues of a nonclonal system of recognition. 
 
Cell.
 
91:295–298.
5. Gonzalez-Aseguinolaza, G., L.V. Kaer, C.G. Bergmann, J.M.
Wison, J. Schmieg, M. Kronenberg, T. Nakayama, M. Tani-
guchi, Y. Koezuka, and M. Tsuji. 2002. Natural killer T cell
ligand 
 
 
 
-galactosylceramide enhances protective immunity
induced by malaria vaccines. 
 
J. Exp. Med. 
 
195:617–624.
6. Bendelac, A., M. Bonneville, and J.F. Kearney. 2001. Au-
toreactivity by design: innate B and T lymphocytes. 
 
Nat. Rev.
Immunol.
 
 1:177–186.
7. Steinman, R.M., and M.C. Nussenzweig. 2002. Inaugural
Article: Avoiding horror autotoxicus: The importance of
dendritic cells in peripheral T cell tolerance. 
 
Proc. Natl. Acad.
Sci. USA.
 
 99:351–358.
8. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like recep-
tors: critical proteins linking innate and acquired immunity.
 
Nat. Immunol.
 
 2:675–680.
9. Kimbrell, D.A., and B. Beutler. 2001. The evolution and ge-
netics of innate immunity. 
 
Nat. Rev. Genet.
 
 2:256–267.
10. Krutzik, S.R., P.A. Sieling, and R.L. Modlin. 2001. The role
of Toll-like receptors in host defense against microbial infec-
tion. 
 
Curr. Opin. Immunol.
 
 13:104–108.
11. Lemaitre, B., E. Nicolas, L. Michaut, J.-M. Reichhart, and
J.A. Hoffmann. 1996. The dorsoventral regulatory gene cas-
sette spatzle/Toll/cactus controls the potent antifungal re-
sponse in drosophila adults. 
 
Cell.
 
 86:973–983.
12. Schnare, M., G.M. Barton, A.C. Holt, K. Takeda, S. Akira,
and R. Medzhitov. 2001. Toll-like receptors control activa-
tion of adaptive immune responses. 
 
Nat. Immunol.
 
 2:947–
950.
13. Michel, T., J.M. Reichhart, J.A. Hoffmann, and J. Royet.
2001. Drosophila Toll is activated by Gram-positive bacteria
through a circulating peptidoglycan recognition protein. 
 
Na-
ture.
 
 414:756–759.
14. Horng, T., G.M. Barton, and R. Medzhitov. 2001. TIRAP:
an adapter molecule in the Toll signaling pathway. 
 
Nat. Im-
munol.
 
 2:835–841.
15. Fitzgerald, K.A., E.M. Palsson-McDermott, A.G. Bowie,
C.A. Jefferies, A.S. Mansell, G. Brady, E. Brint, A. Dunne, P.
Gray, M.T. Harte, et al. 2001. Mal (MyD88-adapter-like) is
required for Toll-like receptor-4 signal transduction. 
 
Nature.
 
413:78–83.
16. Kawai, T., O. Takeuchi, T. Fujita, J. Inoue, P.F. Muhlradt,
S. Sato, K. Hoshino, and S. Akira. 2001. Lipopolysaccharide
stimulates the MyD88-independent pathway and results in
activation of IFN-regulatory factor 3 and the expression of a
subset of lipopolysaccharide-inducible genes. 
 
J. Immunol.
 
 167:
5887–5894.
17. O’Rourke, L.M., R. Tooze, M. Turner, D.M. Sandoval,
R.H. Carter, V.L. Tybulewicz, and D.T. Fearon. 1998.
CD19 as a membrane-anchored adaptor protein of B lym-
phocytes: costimulation of lipid and protein kinases by re-
cruitment of Vav. 
 
Immunity.
 
 8:635–645.
18. Dempsey, P.W., M.E. Allison, S. Akkaraju, C.C. Goodnow,
and D.T. Fearon. 1996. C3d of complement as a molecular
adjuvant: bridging innate and acquired immunity. 
 
Science.
 
271:348–350.
19. Natori, T., M. Morita, K. Akimoto, and Y. Koezuka. 1994.
Agelasphins, novel antitumor and immunostimulatory cere-
brosides from the sponge 
 
Agelas mauritianus.
 
 
 
Tetrahedron.
 
 50:
2771–2784.
20. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K.
Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al.
1997. CD1d-restricted and TCR-mediated activation of
valpha14 NKT cells by glycosylceramides. 
 
Science.
 
 278:1626–
1629.
21. Singh, N., S. Hong, D.C. Scherer, I. Serizawa, N. Burdin,
M. Kronenberg, Y. Koezuka, and L. Van Kaer. 1999. Cut-
ting edge: activation of NK T cells by CD1d and alpha-galac-
tosylceramide directs conventional T cells to the acquisition
of a Th2 phenotype. 
 
J. Immunol.
 
 163:2373–2377.
22. Carnaud, C., D. Lee, O. Donnars, S.-H. Park, A. Beavis, Y.
Koezuka, and A. Bendelac. 1999. Cross-talk between cells of
the innate immune system: NKT cells rapidly activate NK
cells. 
 
J. Immunol.
 
 163:4647–4650.
23. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A.
Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van
Kaer, et al. 1999. The natural killer T (NKT) cell ligand al-
pha-galactosylceramide demonstrates its immunopotentiat-
ing effect by inducing interleukin (IL)- 12 production by
dendritic cells and IL-12 receptor expression on NKT cells. 
 
J.
Exp. Med.
 
 189:1121–1128.
24. Eberl, G., and H.R. MacDonald. 2000. Selective induction
of NK cell proliferation and cytotoxicity by activated NKT
cells. 
 
Eur. J. Immunol.
 
 30:985–992.
25. Ridge, J.P., F. Di Rosa, and P. Matzinger. 1998. A condi-
tioned dendritic cell can be a temporal bridge between a
CD4
 
 
 
 T- helper and a T-killer cell. 
 
Nature.
 
 393:474–478.
26. Schoenberger, S.P., R.E. Toes, E.I. van der Voort, R. Of-
fringa, and C.J. Melief. 1998. T-cell help for cytotoxic T
lymphocytes is mediated by CD40-CD40L interactions. 
 
Na-
ture.
 
 393:480–483.
27. Bennett, S.R., F.R. Carbone, F. Karamalis, R.A. Flavell, J.F.
Miller, and W.R. Heath. 1998. Help for cytotoxic-T-cell re-
sponses is mediated by CD40 signalling. 
 
Nature.
 
 393:478–
480.
28. Kakimi, K., L.G. Guidotti, Y. Koezuka, and F.V. Chisari.
2000. Natural killer T cell activation inhibits hepatitis B virus
replication In vivo. 
 
J. Exp. Med.
 
 192:921–930.
29. Gonzalez-Aseguinolaza, G., C. de Oliveira, M. Tomaska, S.
Hong, O. Bruna-Romero, T. Nakayama, M. Taniguchi, A.
Bendelac, L. Van Kaer, Y. Koezuka, and M. Tsuji. 2000. al-
pha-galactosylceramide-activated Valpha 14 natural killer T 
F23
 
Bendelac and Medzhitov
cells mediate protection against murine malaria. 
 
Proc. Natl.
Acad. Sci. USA.
 
 97:8461–8466.
30. Toura, I., T. Kawano, Y. Akutsu, T. Nakayama, T. Ochiai,
and M. Taniguchi. 1999. Cutting edge: inhibition of experi-
mental tumor metastasis by dendritic cells pulsed with alpha-
galactosylceramide. 
 
J. Immunol.
 
 163:2387–2391.
31. Hong, S., M.T. Wilson, I. Serizawa, L. Wu, N. Singh, O.V.
Naidenko, T. Miura, T. Haba, D.C. Scherer, J. Wei, et al.
2001. The natural killer T-cell ligand alpha-galactosylcer-
amide prevents autoimmune diabetes in non-obese diabetic
mice. 
 
Nat. Med.
 
 7:1052–1056.
32. Sharif, S., G.A. Arreaza, P. Zucker, Q.S. Mi, J. Sondhi, O.V.
Naidenko, M. Kronenberg, Y. Koezuka, T.L. Delovitch,
J.M. Gombert, et al. 2001. Activation of natural killer T cells
by alpha-galactosylceramide treatment prevents the onset
and recurrence of autoimmune type 1 diabetes. 
 
Nat. Med.
 
7:1057–1062.
33. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A syn-
thetic glycolipid prevents autoimmune encephalomyelitis by
inducing TH2 bias of natural killer T cells. 
 
Nature.
 
 413:531–
534.
34. Singh, A.K., M.T. Wilson, S. Hong, D. Olivares-Villago-
mez, C. Du, A.K. Stanic, S. Joyce, S. Sriram, Y. Koezuka,
and L. Van Kaer. 2001. Natural killer T cell activation pro-
tects mice against experimental autoimmune encephalomy-
elitis. 
 
J. Exp. Med.
 
 194:1801–1811.
35. Wang, B., Y.B. Geng, and C.R. Wang. 2001. CD1-restricted
NK T cells protect nonobese diabetic mice from developing
diabetes. 
 
J. Exp. Med.
 
 194:313–320.
36. Jahng, A.W., I. Maricic, B. Pedersen, N. Burdin, O. Nai-
denko, M. Kronenberg, Y. Koezuka, and V. Kumar. 2001.
Activation of natural killer T cells potentiates or prevents ex-
perimental autoimmune encephalomyelitis. 
 
J. Exp. Med.
 
 194:
1789–1799.
37. Cui, J., N. Watanabe, T. Kawano, M. Yamashita, T. Kamata,
C. Shimizu, M. Kimura, E. Shimizu, J. Koike, H. Koseki, et
al. 1999. Inhibition of T helper cell type 2 cell differentia-
tion and immunoglobulin E response by ligand-activated
Valpha14 natural killer T cells. 
 
J. Exp. Med.
 
 190:783–792.
38. Gallucci, S., M. Lolkema, and P. Matzinger. 1999. Natural
adjuvants: endogenous activators of dendritic cells. 
 
Nat. Med.
 
5:1249–1255.
39. Sauter, B., M.L. Albert, L. Francisco, M. Larsson, S. Somer-
san, and N. Bhardwaj. 2000. Consequences of cell death: ex-
posure to necrotic tumor cells, but not primary tissue cells or
apoptotic cells, induces the maturation of immunostimulatory
dendritic cells. 
 
J. Exp. Med.
 
 191:423–434.
40. Basu, S., R.J. Binder, R. Suto, K.M. Anderson, and P.K.
Srivastava. 2000. Necrotic but not apoptotic cell death re-
leases heat shock proteins, which deliver a partial maturation
signal to dendritic cells and activate the NF-kappa B path-
way. 
 
Int. Immunol.
 
 12:1539–1546.
41. Matzinger, P. 1998. An innate sense of danger. 
 
Semin. Immu-
nol.
 
 10:399–415.
42. Matzinger, P. 1994. Tolerance, danger and the extended
family. 
 
Annu. Rev. Immunol.
 
 12:991–1045.